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ABSTRACT
Pathologically-Validated Tumor Prediction Maps in MRI

Alex Barrington
Marquette University, 2019

Glioblastoma (GBM) is an aggressive cancer with an average 5-year
survival rate of about 5%. Following treatment with surgery, radiation, and
chemotherapy, diagnosing tumor recurrence requires serial magnetic resonance
imaging (MRI) scans. Infiltrative tumor cells beyond gadolinium enhancement on
T1-weighted MRI are difficult to detect. This study therefore aims to improve
tumor detection beyond traditional tumor margins. To accomplish this, a neural
network model was trained to classify tissue samples as ‘tumor’ or ‘not tumor’.
This model was then used to classify thousands of tiles from histology samples
acquired at autopsy with known MRI locations on the patient’s final clinical MRI
scan. This combined radiological-pathological (rad-path) dataset was then
treated as a ground truth to train a second model for predicting tumor presence
from MRI alone. Predictive maps were created for seven patients left out of the
training steps, and tissue samples were tested to determine the model’s
accuracy. The final model produced a receiver operator characteristic (ROC)
area under the curve (AUC) of 0.70. This study demonstrates a new method for
detecting infiltrative tumor beyond conventional radiologist defined margins
based on neural networks applied to rad-path datasets in glioblastoma.
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I.INTRODUCTION

According to the American Brain Tumor Association (ABTA), almost
80,000 people will be diagnosed with a brain tumor this year, and 16,000 people
will die from a brain tumor this year (Brain tumor FAQs | ABTA.). Glioblastoma
(GBM), a World Health Organization (WHO) grade IV astrocytoma, is an
aggressive glial tumor with a poor 5-year survival rate of 5% (Brain tumor –
statistics, 2018; Tamimi & Juweid, 2017). These tumors are diagnosed with a
combination of imaging techniques and tissue samples acquired during surgery
or biopsy (Brain tumor – diagnosis, 2018). Research on the exact initial cause of
GBMs is still limited, however, these tumors can develop from lower-grade
gliomas, such as grade II or grade III astrocytomas (Development of glioblastoma
multiforme.; Forst, Nahed, Loeffler, & Batchelor, 2014).
Glioblastoma Multiforme
GBMs are classified as one of three genetic subtypes, based variations of
isocitrate dehydrogenase (IDH): IDH-wildtype, IDH-mutant, and not otherwise
specified (NOS). Additionally, IDH-wildtype has three subtypes: giant cell
glioblastoma, gliosarcoma, and, most recently added, epithelioid glioblastoma.
IDH-wildtype accounts for around 90% of GBMs diagnosed (Louis et al., 2016).
These are generally de novo cases, while the IDH-mutant varieties commonly
develop from lower grade gliomas (LGGs) (Ohgaki & Kleihues, 2013). These two
varieties also show trends in the ages when they develop. IDH-wildtype is
generally diagnosed in patients with a median age around 62, while the mutant
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variety has a median age of 44 (Louis et al., 2016). Additional differences
between the two include median survival, where IDH-wildtype is about 15 months
and IDH-mutant is 31 months, the location of the tumor, with the IDH-wildtype
developing most anywhere in the cerebrum and the IDH-mutant developing in the
frontal lobe, and apparent necrosis, which is widespread in IDH-wildtype and
seen much less in IDH-mutant (Ellingson, B. M. et al., 2013; Louis et al., 2016).
Invasive GBM tumor cells spread in a diffuse manner lacking a defined
tumor boundary beyond the core (The life of a brain tumor: How does
glioblastoma grow? – penn medicine.), often following white matter tracts
(Mickevicius et al., 2015). Abnormal tissue outside of contrast enhancing margins
can be seen as hyperintense regions on a T2-weighted fluid attenuated inversion
recovery (FLAIR) MRI scan. These hyperintense regions are thought to be a
combination of non-contrast-enhancing tumor (nCET), and vasogenic edema
associated with an inflammatory response. Another treatment related imaging
artifact is known as pseudo-progression, which occurs during the first 12 weeks
after the standard of care treatment administration of radiation and
temozolomide, and manifests as contrast enhancement not associated with
viable tumor (Melguizo-Gavilanes, Bruner, Guha-Thakurta, Hess, & Puduvalli,
2015; Villanueva-Meyer, Mabray, & Cha, 2017). Although there have been
studies showing the efficacy of multi-parametric MRI techniques, they generally
use biopsy samples, which is not necessarily representative of the entire
underlying tissue (Kazerooni et al., 2018; Kimura & da Cruz, L. Celso Hygino,
2016; Yang, X. et al., 2019). Additionally, areas adjacent to the bright area on an
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MRI may contain viable tumor or pseudoresponse (Nguyen et al., 2016;
Villanueva-Meyer et al., 2017). Differentiating these processes from tumor
growth, response to treatment, and treatment effects is difficult and puts
increasing pressure on optimizing surgical resection to be correct and sufficient
(Li, Suki, Hess, & Sawaya, 2016; Villanueva-Meyer et al., 2017). Therefore, an
understanding of how multimodal imaging signatures relate to the underlying
tissue pathology is critical to better treatment direction.
Research has shown that poorer prognosis, IDH-mutant status, and
decreased survival are all correlated with the presence of nCETs (Cohen-Gadol,
DiLuna, Bannykh, Piepmeier, & Spencer, 2004; Jain et al., 2014; Kotrotsou et al.,
2018; Lasocki, Gaillard, Tacey, Drummond, & Stuckey, 2016; Lasocki, Gaillard,
Tacey, Drummond, & Stuckey, 2018; Li et al., 2016). These nCETs are regions
of tumor that do not show up on T1-weighted with gadolinium contrast (T1C)
scans but can usually be seen in FLAIR images. These have a less distinct
boundary, similar to what is seen in the histology of the tumor. Because of the
importance of the nCETs in prognosis, imaging, and treatment, capturing this
information is critical to accurate surgical resection and estimating the spread of
the tumor (Li et al., 2016). Therefore, an understanding of how multimodal
imaging signatures relate to the underlying tissue pathology is critical to better
treatment direction.
The Mayo Clinic states that "a biopsy is the only way to definitively
diagnose a brain tumor and give a prognosis to guide treatment decisions"
(Glioma | diagnosis and treatment, 2019). However, when a tumor cannot be
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biopsied, a diagnosis is made on the imaging alone, which could miss key areas
such as nCETs (How we diagnose brain tumors.). Despite the pathological
aspect of this tumor being key to an exact diagnosis, many tumor prediction and
segmentation algorithms that exist only use MRI to predict tumor (University of
Pennsylvania, 2018).
Machine Learning
The 2018 MICCAI Multimodal Brain Tumor Segmentation Challenge used
board-certified neuroradiologist-annotated MRI scans to produce a dataset of T1weighted (T1), T1C, T2-weighted (T2), and fluid-attenuated inversion recovery
(FLAIR) images with edema, tumor core, necrosis, and whole tumor annotations
(University of Pennsylvania, 2018). While this type of challenge is good in
practice to assist in annotation and speed up a radiologist's heavy workload, the
underlying pathology may not be adequately identified. The 2014 MICCAI Brain
Tumor Digital Pathology Challenge proposed two challenges, one for classifying
between LGG and GBM on whole slide images (WSI), and the other for
segmenting necrotic regions (MICCAI 2014 grand challenges, 2016). Neither
challenge involved segmenting tumor from no tumor in brain tissue, so none of
the resulting models from that challenge will segment brain tumor without
additional training. In the paper by Xu, AlexNet transfer learning was proved to
be useful with histological images, particularly with brain tumor pathology (Xu et
al., 2017). Many other examples of AlexNet's performance has been
demonstrated in open datasets and clinical datasets (Lu, S., Lu, & Zhang, 2019;
Yang, Y. et al., 2018). These examples of successful transfer learning using
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AlexNet as well as MATLAB’s ease of use to implement a pre-trained AlexNet
model were the main reason that AlexNet was used as the architecture for this
histological prediction model. However, while Xu demonstrated good results with
LGG vs GBM classification, necrosis segmentation, and colon cancer
segmentation, tumor segmentation in brain tissue was not demonstrated due to
the limitation of 2014 MICCAI dataset (MICCAI 2014 grand challenges, 2016; Xu
et al., 2017). Because of this, there is no specific model to be able to compare
our results to, rather just a speculative comparison between existing AlexNet
transfer learning models.
Machine learning is widely used in both cancer research and the clinical
setting for its ability to quickly and reliably identify tumor masses as well as
potential outcomes for a variety of cancer types (Bakas et al., 2018; Kourou,
Exarchos, Exarchos, Karamouzis, & Fotiadis, 2015; Lu, C. et al., 2018;
Manogaran et al., 2018; Rathore et al., 2019; University of Pennsylvania, 2018;
Varuna Shree & Kumar, 2018; Zijlstra, Novitskaya, Vizio, Reis- Sobreiro, &
Freeman, 2019). There are a seemingly myriad number of articles describing
machine learning development, uses, and applications, but most do not use a
histological bases for their studies. For example, Kumar uses radiological scans
only and uses a texture analysis to segment tumor (Vijay Kumar & GV Raju,
2010). Dong also uses radiological scans, borrowing the 2015 BRATS dataset
(Dong, Yang, Liu, Mo, & Guo, 2017). However, as stated previously, samples of
tissue are the only way to exactly diagnose a brain tumor (Brain tumor diagnosis, 2018; Glioma | diagnosis and treatment, 2019). In order to have more
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accurate models being trained on MRI data, the underlying histology ought to be
included. There is therefore a gap in the validity of the underlying truth used to
train current tumor prediction models. This underlying histology can be registered
and brought into MRI-space to align with the MRI scans using previously
established methods (LaViolette et al., 2014; McGarry et al., 2016). Once a
histological dataset is created, improved MRI predictions based on underlying
histology can occur, which is the goal of this project.
This project creates such a dataset and then makes use of a machine
learning classification scheme where a small dataset is used to create a much
larger dataset, which is then used as ground truth for a final classification.
Described in the methods, this project takes a set of 1402 tiles and labels and
produces a model. Then that model is used to create ground truth for a new
model to be trained using MRI. While there are many existing articles using
weakly supervised learning (Bukowy et al., 2019; Ge, Yang, & Yu, 2018;
Mlynarski, Delingette, Criminisi, & Ayache, 2018) similar to the methods used in
this project, few demonstrate the ability to use a small initial dataset to create
ground truth to classify a much larger dataset.
Scope
The long-term goal of this project is to generate models trained with
datasets from patient imaging and aligned histology to better predict the location
of tumor invasion beyond conventionally defined margins. We expect that these
models will then provide oncologists with more accurate tumor detection for
targeting with additional radiation, or for a better targeted biopsy procedure.
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II.METHODS

This study is comprised of two distinct experiments. Experiment 1 deals
solely with histology from autopsy samples, testing the hypothesis that machine
learning models trained with pathologist annotated samples are able to
differentiate regions of viable tumor. The second experiment expands these
models onto a large dataset of histology aligned to MRI scans, to test the
hypothesis that a second algorithm trained with the combined rad-path dataset is
able to predict tumor presence with MRI alone.
Study Population
This IRB approved study, (MCW-PRO17446) included 23 total subjects
(16 male and 7 female). Experiment 1 used the tissue samples and histology
from 15 patients, while Experiment 2 used the imaging from 16 patients. Nine of
the patients overlapped between experiments (Table 1 and 2). Patients in this
study ranged from 41 to 88 years old (median=62yo). Of the 23 patients, 21 had
a final diagnosis of GBM. The other two non-GBM patients (included in
Experiment 2 only to demonstrate model generalizability) had a final diagnosis of
a WHO grade 3 oligodendroglioma and WHO grade 3 astrocytoma.
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Table 1. Per Subject Breakdown of Histological Dataset for Experiment 1.
Subject
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Images
39
19
105
433
66
26
79
27
18
24
66
39
87
328
45

Test Set Tumor
19
1
91
294
32
16
73
10
3
12
24
32
X
57
X
221
X
19

No Tumor
20
18
14
139
34
10
6
17
15
12
42
7
30
107
26

Table 2. Per Subject Breakdown of the MRI Dataset
Subject Images Test Set Tumor No Tumor
2*
1369
X
3*
173
X
5*
406
X
6*
578
11*
575
X
12*
1486
14*
1257
15*
3753
16
954
X
17
156
X
18
4144
19
1969
20
9842
X
21
6429
22
4571
23
16405
* Used in experiment 1.

0
173
201
364
3
853
777
2716
326
0
782
432
9741
2960
1033
4295

1369
0
205
214
572
633
480
1037
628
156
3362
1537
101
3469
3538
12110
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Histological Processing (Experiment 1 & 2)
Patients who have a GBM diagnosis are first consented to undergo
donation of tissue to the Brain Bank in the LaViolette Lab at the Medical College
of Wisconsin. The following process is the same as (Nguyen et al., 2016). At
autopsy, the brains were removed and placed in a 3D printed brain cage during
formalin fixation to maintain structural integrity. The brain tissue fixes in formalin
solution for about two weeks. Once fixed, the brain is then sliced in the same
orientation as the axial MRI using a custom 3D printed slicing jig. Tissue samples
are then taken from those slices. These samples are put onto slides and stained
using hematoxylin and eosin (H&E) to highlight cell nuclei blue/purple and
cytoplasm and extracellular matrix pink. Once these slides are created, they are
then digitized using a slide scanner at 40X magnification. This image is then
down-sampled to 10X magnification. The resulting RGB image is tiled into
2000x2000 pixel images. This process of using smaller, tiled images is similar to
a process Barker uses in the digital processing of their 2016 paper (Barker,
Hoogi, Depeursinge, & Rubin, 2016).
These images produced a dataset that needed to be organized before
proceeding. Nuclei, red blood cells, cytoplasm, and whitespace were extracted
from these images. To do this, original images were scaled to range from 0 to 1
instead of 0 to 255. The image was then transformed into hue, saturation, and
intensity (HSV) space. Any pixels with saturation less than 0.1 and intensity
greater than 0.7 were considered whitespace. Any pixels with saturation greater
than 0.6 and hue greater than .85 or less than 0.05 was considered to be red
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blood cells. The reason a pixel that was either greater than 0.85 or less than 0.05
was used is due to how hue is represented in HSV space. The values from 0 to 1
represent red to yellow to blue to red. Red occupies the regions where hue is
less than .85 and greater than 0.05, so these values were used. Then the
Euclidean distant to red (HSV values of [1 1 1]) from the HSV image was found.
This resulting image was used in part to extract the nuclei. An image of the
Euclidean distance from RGB pink (RGB values of [1 0 1]). The equation to
extract nuclei took the extracted pink and subtracted the extracted red. This was
then multiplied by the inverse of the original scaled RGB image. The red blood
cells were masked out of this image. This image was then converted to grayscale
to create an image that highlighted only nuclei. The remaining extracellular matrix
was extracted as any pixel less than 40% of the maximum value possible in the
pink image. The thresholds for creating these images were set so that there is
minimal to no overlap between what is highlighted in each of the images. All four
of these images, whitespace, red blood cells, nuclei, and extracellular matrix,
were resized to 1% of the original size, which essentially created density maps of
each of these images. This was done in preparation for histological registration to
MRI scans.
A selection of 1402 tiles that were free of artifacts were then chosen as
the dataset. This is significantly smaller than the total number of tiles in the
dataset, which ranges in the millions. Using this small set, a weak classification
scheme was applied to classify the rest of the dataset.
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Dataset Curation and Histology Annotation (Experiment 1)

Figure 1. Example of a slice of brain tissue and its underlying tiles from the
digitized histology. On the far right is an example of how a pathologist might
annotate each tile.

A MATLAB graphical user interface (GUI) was created in order for a
pathologist to classify the selected tiles. This GUI had multiple checkboxes with
descriptive pathological features, such as pseudopalisading necrosis,
hypercellularity, and calcification, as well as whether or not the tile contained
tumor. A board-certified pathologist classified each of the 1402 tiles as containing
tumor or not containing any tumor (EJC). The pathological features were not
used for this study but will most likely be used in future research.
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Figure 2. Screenshot of the GUI created for pathologist annotations.

After the 1402 images were classified by the pathologist, three patients
were randomly selected to be left out of the training dataset. 163 images without
tumor and 298 images with tumor were left out to be tested on from these three
left-out patients. One subject had a high number of images (294 total images
from one subject) which caused the number of images in the tumor-containing
training dataset to be much higher than the no-tumor-containing set. After class
balancing the training dataset, 334 no tumor class images and 334 tumor class
images were then used to train a pretrained AlexNet convolutional neural
network (CNN) to identify if an image contained tumor (Krizhevsky, Sutskever, &
Hinton, 2012). This CNN was pretrained using the ImageNet dataset (ImageNet,
2016), which is a set of more than 14 million images that are categorized in 27
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high-level natural image categories and have up to several thousand
subcategories. The architecture of this network is shown in Figure 3. 25% of the
remaining images were used for validation. Data augmentation for this dataset
included rotations of 90, 180, and 270 degrees, as well as flipping vertically and
horizontally.

Figure 3. AlexNet architecture.

Table 3. Breakdown of Histological Dataset.
Train Test Total
Images

Used in
Training

Tumor 607

298

905

334

No Tumor 334

163

497

334

Total Images 941

461

1402

668
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Figure 4. Design diagram for experiment 1 and the training and testing of
the histological tumor classifier.

Training Histological Model
The final CNN output layer gave a percent confidence ranging from 0 to 1
with 0 indicating no tumor presence and 1 indicating high confidence in tumor
presence in the input tile. The input, as constrained by the pretrained AlexNet
network, was a 227x227 RGB image. Since the images were 2000x2000, they
were down-sampled to the AlexNet input size. The network, which was trained
across 4 K80 GPUs using MATLAB 2018a, trained with a learning rate of .001
over the course of 500 epochs. The training completed in about 6 hours. After
training finished, it was applied across all digitized slide samples. The input was
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a 2000x2000 tile that was extracted from the image and then down-sampled.
Then a stride of 200 pixels was used to classify areas across the image, which
effectively created a predicted heatmap that was .5% of the original 10X image.
This is shown in Figure 5.

Figure 5. Example of how the prediction map is created. Each black
bounded box is predicted, then the next image 200 pixels over is predicted and
so on.

In order to have a test-set on an entire slide, a board-certified pathologist
drew ROIs of tumor on slides. Binary masks of tumor were created as ground
truth. These masks were binarily dilated with a square structure element with a
width of 1000 pixels. This was done because if the images fed into the network
may contain tumor in half of the image, it will classify the image as tumor, even if
the underlying pixel in the ground truth is not in the ROI drawn. In this way, a
dilated image is most representative of what the model will predict.
MRI Processing (Experiment 2)
MRIs were acquired using a GE MR system or Siemens system. The MRI
closest to a patient's date of death was used for analysis. These varied in
magnetic strength due to the scans being on different machines. 9 of the scans
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were at 3T, 5 of these scans were at 1.5T, and 2 were on a Siemens system at
1.5T; the two sessions from a Siemens system were not used during training. T1,
T1C, FLAIR, and diffusion weighted images (DWI) (diffusion weights or b-values:
b = 0 and b = 1000 s/mm2) were all acquired during these scans. The time
between imaging and death ranged from 5 days to 184 days (median=42 days).
The scans from these sessions required preprocessing. First, all scans
were converted from DICOM images to NIfTI files. Apparent diffusion coefficient
(ADC) maps were then created from the DWI images. This is done by taking the
logarithm of the DWI image with b-value > 0 divided by the DWI image with bvalue = 0. Then dividing this by 1 over the b-value > 0, shown in Equation 1.
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1. 𝐴𝐷𝐶 = log

𝐷𝑊𝐼1000
𝐷𝑊𝐼0

All images were then registered to each subject's FLAIR images, which
were 512x512x22 volumes of .43x.43x5mm^3. Brain masks were extracted from
the registered images. To extract the brain masks, ROBEX, a robust skull
stripping algorithm for T1-weighted images, was used (Iglesias, Liu, Thompson,
& Tu, 2011). This was chosen over the conventional brain extraction tool (BET)
or skull stripping because of its better performance, specifically on populations
with abnormal anatomy such as a tumor or enlarged ventricles (Smith, 2002).
After a brain mask was created, the standard deviation within the brain mask was
calculated to normalize the dataset. This was done in the same process as the
2018 Ellingson paper (Ellingson, Benjamin M. et al., 2018). After normalization,
T1-subtraction maps were created, again in the same process as the 2018
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Ellingson paper (Ellingson et al., 2018). Used in this project were the T1, T1 plus
contrast (T1C), FLAIR, and ADC scans.
The images created from the histology classifier were then co-registered
to the processed MRI images using custom MATLAB software. These steps are
the same processing steps as in the 2014 LaViolette paper (LaViolette et al.,
2014). Because the tissue was cut in approximately the same plane as the MRI
scans, these can be compared and co-registered through this process. This
process warps the tissue into MRI-space and aligns it with the last scan of the
patient’s brain. Regions of interest (ROIs) are drawn on the tissue and matched
MRI so that artifacts can be avoided. This produces a set of ROIs of both the
tissue and MRI and their coordinates. These were aggregated into 10x10 voxel
ROIs in MRI-space.
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Training MRI Model (Experiment 2)

Figure 6. Illustration of the experimental design for Experiment 2. The
model trained in Experiment 1 is first applied to whole slide images. The
prediction maps are then brought into MRI space for comparison to the coregistered MRI patches. These patches and the tumor prediction values were
then used to train a second classifier which was then mapped into MRI space.

Using the tumor/no tumor classification, generated from the histology
model predicting iteratively across the slides, as ground truth, an additional CNN
was trained to find tumor in MRI. The sum of all histological tumor predictions in
an ROI was used as the label. Because the size of the tissue ROI was 10x10
pixels, the underlying value for the tumor prediction was a 100-value max, the
sum of those pixels. Tumor was considered to be anything that was above a sum
of 10 in total. 10x10 voxel ROIs of T1, T1C, FLAIR, and ADC were input to the
network. The network architecture is shown in Figure 8. This network was trained
on 9 different subjects and tested on 7 additional subjects for a total of 16
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subjects in the dataset. A total number of 54067 ROIs were given from this
dataset, with 32473 ROIs used for training and 21594 ROIs used for testing. 7
subjects were removed from the training set for testing as well as 20% of the
training dataset.

Figure 7. MRI model architecture.

Table 4. Breakdown of the MRI Dataset
Train Test
Subjects 9

7

Tumor ROIs (sum of pixels > 10) 11369 13287
No Tumor ROIs (sum of pixels < 10) 21104 8307
Total ROIs 32473 21594

Total
16
24656
29411
54067

The training used a learning rate of 0.01 and trained over 100 epochs. The
trained network was then applied voxel-wise with T1, T1C, FLAIR, and ADC as
the inputs to produce the final output, which is the same size as the input. This
effectively gives a heatmap of active tumor regions with a score of 0 to 1, 0 being
confidently not tumor and 1 being confidently tumor.
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III.RESULTS

Histology
The histology tumor classifier ran for 500 epochs and ended with a final
training accuracy of 89.6% and a loss of .201. Within the test-set, the area under
the curve (AUC) for the receiver operating characteristic (ROC) curve was .745,
shown in Figure 88, and an accuracy of 70.1%. The test-set contained only naïve
subject images. Additionally, entire slides were tested from the same naïve testset of subjects. Using pixel-wise comparison of annotations done by the
pathologist and the tumor predicted in the WSI, three slides were analyzed. Only
pixels within the tissue were used for comparison. 25749 pixels were extracted
from the images. This resulted in an overall accuracy of 90.15% and an AUC
of .92, shown in Figure 9.
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Figure 8. ROC for the test set of the histological classifier. An AUC of .745
was achieved.

Figure 9. ROC for the histological classifier within the pixelwise
comparison of multiple test-set images that a pathologist had annotated. Here,
AUC of .920 was achieved.

Figure 10 shows an example of the input, output, and both images
combined. This is an example of a novel slide from a patient that was within the
training dataset. This is a good example of the classifier avoiding regions of
necrosis, seen in the middle of the tissue, but highlighting areas of active tumor.
The classifier also did not consider areas of artifact as tumor. However, it did
wrongly classify some regions of an artifact in the image. The artifact, at the
bottom of the image, is the edge of the coverslip. This type of image artifact was
not something presented to the classifier during training because all artifacts
were discarded.
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Figure 10. Digitized tissue sample (left), histological tumor prediction
heatmap (middle), and the heatmap overlaid on the tissue (right). This is an
example of a slide that was processed using the histological classifier.

Two examples of the test-set are shown below in Figure 11 and Figure 12.
The first example shows how well the model did on a naïve subject. The second
example shows a naïve subject where the model performed poorly.
Shown in Figure 11, the area of tumor, annotated by the pathologist, seem
to be picked up well by the classifier. While the entire right piece of tissue was
tumor, the classification on the left piece of tissue followed the same pattern as
the annotation by the pathologist. Figure 12 shows some areas where the
prediction follows the annotations, but many areas where it missed.
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Figure 11. Original tissue a) from a test subject shown with pathologist’s
annotation of areas of tumor b). The prediction overlaid on the tissue c) and the
prediction itself d) are on a scale of dark blue to yellow: dark blue meaning high
confidence that the area contains no tumor and yellow meaning high confidence
that tumor is in this area. Shown in e), both the annotation by the pathologist
(blue) and the prediction (red) are combined to show how well the two images
align. The image in f) is the pathologist’s annotations binarily dilated by a square
of 1000x1000pixels. This image is the same image in blue seen in e).
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Figure 12. Another example of tissue from a test subject, displayed in the
same fashion as Figure 11. This was an example where the model failed in
multiple areas. Figure 13 goes into detail about where the model failed in this
example.

Figure 13 goes into detail where the model failed for the example tissue in
Figure 12. There are areas of necrosis where the model tends to be about 50%
accurate. Additionally, while the model was correct in this image around areas of
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sulci and dura, this is usually variable upon qualitative inspection. These areas
are usually masked out if possible. Seen in Figure 13 b), an area of tumor was
also misclassified, which the model predicted as mostly not containing tumor.
The model also completely avoided the bubble artifact on the lower middle of the
image. Because the model avoided this area, it did miss areas of tumor in this
region.
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Figure 13. Examples from the overall tissue a) are representative of where
the model tends to fail. The area of b) was an area that the model missed an
area of tumor. In c), the model was mostly correct, though areas in the bottom
right of this image and below this image were tumor and the model did not
predict tumor. Both d) and e) are areas of necrosis that the model predicted
contained tumor. The model incorrectly predicted tumor in d) where there was
none and correctly in e).

The part of the MRI training set produced by this image would not include
the artifact region because of how the ROIs are selected during tissue
registration to MRI, therefore, this misclassification should not persist in the MRI
training. The ROI selection process is a manual process by which the researcher
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marks boxes that are clear of artifacts and parts of tissue that are not useful or
not relevant (e.g. an area of dura).
MRI
The MRI classifier was not quite as accurate as the histological classifier.
The training accuracy converged to 83.1% over 100 epochs with a loss of .430.
Checking against a test-set, the AUC was nearly .70, shown in

Figure 14, and an accuracy of 73.3%.

Table 5. Breakdown of Training Information on the Histological and MRI
Models
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Epochs Final
Final
training
loss
accuracy (%)
Histology 500
89.6
.201
MRI 100

83.1

.430

Test
accuracy
(%)
70.1

Test
AUC

73.3

.696

.745

Figure 14. ROC for the MRI classifier. AUC of .696 was achieved.

This ROC curve shows subtle predictive utility for the MRI classifier within
the test-set. However, as with the histological classifier, when applying the
classifier to an entire image, it is clear that the test-set ROC is not entirely
representative.
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Figure 15 shows two examples of the final output. This is an example of tissue
that has a clearly defined tumor, highlighted in the T1C scan, but also identified
by the MRI model.

Figure 15. Example of two different MRI slices from a subject within the test-set
a). MRI tumor prediction heatmap b) shows areas of red that are confidently
tumor and areas of dark blue are confidently not tumor. This is the same for the
images on the right, which are the underlying histological tumor prediction c) and
the histological tumor prediction binarily eroded by a square of 10x10pixels d).
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Similar to the analysis of the histology classifier, there was a
morphological operation performed before comparing the images. In

Figure 15 d), the ground truth of the histological prediction was grayscale-eroded
by a 10x10 square. Since the histological prediction is a much larger region that
what is actually tumor, this was done to show the accuracy of the MRI predictor.
And while the images shown in
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Figure 15 c) of the original histological tumor prediction are fairly widespread,
eroding them shows their similarity to the tumor prediction in MRI.
A representative slice from each of the test patients, along with their
conventional imaging is shown in Figure 16. Figure 17 shows a validation sample
taken from a test patient indicating where tumor was found compared to the
predictive map. The annotation by the pathologist on the tissue sample is also
shown. This is an example where tumor was found outside of conventionally
defined radiologic boundaries, with no contrast enhancement and very little
FLAIR hyperintensity, having areas of tumor confirmed by the pathologist and by
both models.
.
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Figure 16. A representative MRI slice from each of the test set subjects
from the MRI portion of this study.
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Figure 17. A representative sample of tissue, histology, and MRI (tissue
outlined in a yellow box). This sample shows non-enhancing tumor that was
predicted in both the histological and MRI models and was annotated by our
pathologist.
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IV. DISCUSSION

This study found that deep learning models were able to identify areas of
tumor in both histological samples and MRI images. The analysis of the whole
slide images showed how well the classifier was able to predict various areas of
tumor with an accuracy of 90.15%, which was well above the accuracy of 70.1%
on the test set images alone. The MRI classifier had poor test set results, with an
accuracy of 73.3%, but well-represented the underlying tissue upon qualitative
inspection.
The histological model performed very well on areas of hypercellularity
and infiltrative tumor. Though the model had good accuracy when it comes to the
whole slide images, there were a number of specific areas where the classifier
tended to fail. The histological model tended to avoid areas of gray matter,
despite some areas of tumor. This is consistent with the fact that GBMs are
generally found in areas of white matter. Because of this, the training set did not
contain many areas of gray matter infiltration. While areas of white matter were
usually classified accurately, the model did not generalize well enough to identify
tumor appearing in gray matter within the test-set. The model also classified
areas of tissue artifacts (tears, blurs, etc.) as not tumor, despite some areas of
tumor being present. This is difficult to avoid without giving the model training
images with artifacts present. However, this runs the risk of the model identifying
all areas containing artifacts as containing tumor. One last area where the model
occasionally failed was areas that contained both edema and high vascularity,
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classified as not tumor, which in some cases was wrong. These areas are
particularly important to be able to be correctly identified, particularly because
they have imaging biomarkers that can be shown in MRI (Batchelor et al., 2013;
Lin, 2013; McGahan et al., 2017). These cases can be seen in Figure 13.
While a segmentation model may have been able to show better accuracy
on a test set, a segmentation model is not a practical or effective solution to this
problem. A pathologist would have to create annotations on hundreds or
thousands of images. This is much more difficult than simply saying an image
does or does not contain tumor. Additionally, a pathologist will be hesitant to
create a definitive tumor boundary on a small image. GBMs tend to have diffuse
boundaries that are more like a gradient than a boundary. Because of this, a
dataset produced from many small segmented tiles will be much more inaccurate
than the dataset produced here from many categorized tiles. A segmentation
model could be produced from the outputs of this model in the future, but
currently, this method of creating maps of active tumor in histology using a wellcategorized dataset ought to be used as the new standard of GBM tumor
prediction.
The MRI model achieved a test set AUC of .70. While this is not
exceptional, this should not be discounted given the context and the limitations of
the noisy and clinical dataset. Additionally, the tumor prediction maps generated
by this model creates images that accurately represent the histology. This is
much more representative of the model's performance than just a test set
accuracy. This low AUC leaves room for improvement while establishing
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methods to be used in the future, especially considering this AUC may not be
representative of the model’s performance. However, generalizability is a
concern. MRIs put into this network ought to be processed in the same fashion
and have similar ranges of values.
The final AUC of the MRI model could be influenced and hindered by the
accuracy of the original histological classifier. For example, looking at only the
data that the histological model classified incorrectly, if the MRI classifier was
equally wrong and right for those examples where the histology classifier was
wrong, at best, the AUC may actually be much higher. However, if the MRI model
is classifying the incorrectly classified portions in the same incorrect fashion
(tumor where the original ground truth says there is none and vice versa), then
the .70 AUC may be artificially inflated and may actually be much lower.
In comparison to existing models, some studies demonstrating transfer
learning methods using AlexNet achieve AUCs around .90. However, in many
cases, these are difficult to compare to this project. Yang's 2018 paper yields an
AUC of .966 for their test set using AlexNet (Yang et al., 2018). While this shows
AlexNet's efficacy, their dataset only differentiated LGG from HGG tumor.
Chang's 2018 paper uses AlexNet to differentiate tumor, necrosis, and transition
to necrosis (Chang, Han, Zhong, Snijders, & Mao, 2018). These images are
visually much different from each other, so their accuracy of their models being
above 90% is expected. Another paper shows that AlexNet can achieve an AUC
of .94 in discriminating lung disease using a patch-based input (Hoo-Chang et
al., 2016). Many of these papers are also based on the MICCAI dataset, which
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as stated previously, does not have GBM histology tumor segmentation nor an
MRI dataset verified beyond radiology.
Unconventional Methodology
There were a few instances throughout this project were unconventional
methods were used. A morphological operation of binarily dilating the
pathologist’s annotations was done in order to account for the fact that an image
given to the network may contain tumor on the edge of the image. This is
because the center pixel of that image might in fact be distant from the tumor
boundary itself. A dilation of 1000x1000 pixels was done to approximate what the
tumor would capture if the tumor were in about half of the image. This made the
pathologist’s annotations more representative of what the classifier can capture
since it is only predicting one pixel at a time. A morphological erosion of the
predicted histology in MRI was also performed to qualitatively compare the MRI
prediction maps. A 10x10 grayscale erosion helped account for the same issue
stated previously in the histology model.
Future Work
Future work will include refining both models to increase accuracy. This
will be accomplished by increasing the size of the training dataset given to the
models as well as increasing the resolution of the data itself. For histology, a
resolution of 10X gives a good sense of the general texture of the tissue and
hypercellularity of an area, but a resolution of 40X may be able to show
morphological information of nuclei that a model could use to better predict
tumor. Recent publications have made use of a multi-pathway model for better
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classification (Havaei et al., 2017; Pereira, Pinto, Alves, & Silva, 2016). This
could be employed such that multiple magnifications are represented while
highlighting the center of the image. This would ideally eliminate the need for any
post-processing morphological operations. If a magnification greater than 10X is
included, this may also alleviate some of the issues with the necrosis and edema
misclassification. Having a narrower window of classification may allow for better
detection of areas of tumor.
The threshold for classification in MRI could also be adjusted. A mean
value greater than 10 is considered to contain tumor, but there are regions where
there is plenty of classified tumor in histology where the MRI may not predict
tumor. During a post hoc analysis of this threshold, it was found that using 10 as
a threshold for training and 50 for a threshold for testing dramatically improved
the test set AUC. This could mean that while the model does not perform
exceedingly well on the test set, it is good at finding areas of high tumor
concentration. However, this results in poor sensitivity as evidenced by the test
set AUC.
Multi-class, rather than binary classification, could be employed to avoid
the issues described in Figure 13. This could be done in a hierarchical way. Each
area would be first classified as having artifact or not, and then any areas without
artifacts would be further classified based on tissue type, and then finally
classified based on whether it contains tumor. The final classification would be a
combination of the previous classifications, e.g. white matter containing tumor
free from artifact, gray matter containing no tumor free from artifact, or artifact.
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The dilation and erosion portion of this analysis would also be revisited.
The MRI AUC could be significantly improved by training on an eroded MRI
dataset. Since this is more accurate to what the underlying tumor is, the
signature of tumor within MRI may be able to be found more easily by the model.
Since the post-hoc analysis of eroding the predicted images aligns better with the
predicted tumor in MRI, it is hypothesized that training on these eroded images
may yield better results for the MRI model.
In terms of real-world applications, if the MRI classifier would have had
better generalizable results, this model could be potentially used as a radiological
plug-in at a workstation. This would highlight areas of suspected tumor for the
radiologist to then confirm or reject. This could be used in combination with
existing radiologically based models and would allow a radiologist more
confidence in the underlying pathology.
Limitations
While the accuracy of this model and ROC curve shown in the results do
look promising, as with any study, there are limitations. First, histology slides
contain gigabytes of data that were distilled down to a set of 227x227 RGB tiles.
This is representative of only about 1% of the total data within the slide. While
some of this data may get filtered out anyway, radiomics and pathomics research
has shown that much of a dataset's texture can be used as a good predictor of
labels and outcomes (Barajas et al., 2012; Ellingson, Benjamin M., 2015;
Kickingereder et al., 2012; Kniep et al., 2018; Lu et al., 2018; Rathore et al.,
2018; Tixier, Um, Young, & Veeraraghavan, 2019; Zacharaki et al., 2009; Zhou
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et al., 2018). Ideally, in the future, more of this information will be preserved and
used, but current limitations on processing speed and power hinder development
using such large images in a dataset.
Additionally, the 10x10 ROIs have the opposite problem of the previous
limitation. There is not much data that is fed into the network. Ideally, a better
method would be to use a 10x10 or larger input to a pretrained network. Since
there are not 10x10 pretrained networks that exist, a transfer learning
methodology could not be used directly on this dataset. The only way this could
have been possible would have been to upscale the input data to a size that
something like AlexNet could handle, which would be 227x227 (Krizhevsky,
Sutskever, & Hinton, 2012). This would have created a great deal of artificial data
that would have been given to the network. An attempt was made to locally train
a MNIST dataset CNN model, which would then be used as a transfer learning
model on the MRI dataset. The idea was that since the images are 28x28 in the
MNIST dataset, there would have been minimal upscaling and therefore minimal
artificial data being input to the network. This showed poorer results within the
test set than the final model, most likely due to the upscaling that was performed,
so this method was discarded. Additionally, the fact that this was trained locally
and an established MNIST classifier was not used could have affected the
performance of the model. Another problem with using existing models like
AlexNet was that they can only accept 3 channels as input (Krizhevsky et al.,
2012), but additional MRI volumes could have been added. During tests with
these existing models, the T1 scan was left out because of its generally low
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contrast. Other volumes could include T1 subtraction maps, additional T2 scans,
or diffusion imaging. This would provide more information to the network, which
would be particularly helpful with such a small initial ROI size.
An additional limitation regarding image artifacts should also be noted. In
Figure 10, at the bottom of the image, the edge of the coverslip can not only be
seen but overlaps with the tissue. Because of this overlap, this artifact cannot be
easily removed from processing. While the artifacts in the training images were
removed from the dataset, artifacts that persist in the overall dataset have not yet
been removed. In this case, the model will understandably perform unpredictably
and will have to be masked out. This can be difficult in some cases where, for
example, cover slip edges go across tissue or when marker is drawn on the slide
itself. While the tissue will ideally be processed without artifacts, this is not a
practical assumption.
Once this image is co-registered in MRI-space, ROIs are placed to avoid
areas such as this. Ideally, no images with significant artifacts persisted in the
MRI dataset when that model trained. However, nothing is perfect, and the fact
that it could not be removed in this histological processing should be noted.
Artifacts within the MRI dataset also were not removed prior to training. These
consisted of some minor ringing artifacts, but this nonetheless could be affecting
the MRI model.
The histological model also did not add rotational or translational image
augmentation to the dataset, which could have potentially increased the AUC of
the model. This was done to prevent adding information to an image given to the
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model. This type of image augmentation adds dummy values in for areas created
when rotating or translating. Having a set value being added to areas of the
image is not only adding artificial data into the training set, it could skew the
model depending on what value is chosen to fill these gaps. These dummy
values could potentially skew the training, so those two augmentation methods
were not used.
Pitfalls and Challenges
Originally, the histology tumor classifier was trained on naïve networks
with the input size changed to be 2000x2000x3. This included simple
convolutional networks, a variation of InceptionV4, and a variation of AlexNet.
Despite multiple attempts at training networks in this fashion, they did not
produce an AUC as good as the pretrained AlexNet. They generally ranged
from .6 to .7 for an AUC. In addition to the subpar AUC, upon testing across
entire images, the resulting tumor prediction maps were much more varied and
distributed than the pretrained AlexNet model, showing a lack of generalizability.
This issue persisted with the MRI network as well, but to a greater degree.
The naïve networks used to train on the MRI data tended to overclassify to one
output or one value (e.g. either one category, “tumor”, or one specific prediction
value, .6). This issue was greater in the MRI model due to the limited amount of
data going into the network, particularly because the original MRI dataset used
5x5 voxel ROIs. In all, there were only 100 data points per sample to be
classified (5x5 images from the four scans). This was upped to 400 data points
per example by using 10x10 voxel ROIs. The issue with using naïve networks in
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MRI was overcome by training many different models until one converged
properly.
The histology dataset also changed from the original training set to the
final training set. At first, subjects were dispersed between both the training and
test set, only leaving out a percentage of the images and not images from
specific subjects. In order to accurately test generalizability of the model, images
from some subjects were left out of the training set. The images in the training
set were then class balanced and the remainder of the images were used for
validation during training.
At first, a simple classification tree model was attempted with the MRI
dataset, but while this model achieved a high test-set AUC, it did not generalize
well to MRI slices. This was done either pixel-wise or with a vectorized version of
the 10x10 images. The predictions only tended to highlight edges of the brain
and areas of blood flow. Bagged trees and random forest models were also
tested with similar results. In general, the images produced from these basic
machine learning techniques were highly varied and did not generalize or
highlight areas of tumor, even if they showed good performance on the test-set.
Local development was also a challenge with the histological network. The
size of the images and the number of images needed to train the network were
too large for a single computer to handle. This yielded a necessity for the use of
the MCW Research Computing Center (RCC). The RCC was able to handle
training the AlexNet model and the hundreds of images associated with it in a
matter of hours instead of days. This allowed for many iterations of the model to
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be trained, rather than training one or a few models and hoping that one would
be sufficient. Due to the randomness of shuffling the training dataset, initializing
gradient changes, and changing the hyperparameters of the model, training
many models will generally yield one with much better results than training a few.
Roughly 100 different models were trained on the RCC before one was chosen
that performed at this level. This simply could not have been achieved using local
development only.
This was not an issue with the MRI model. Local development was used
for this training because the tens thousands of images used were only 10x10 and
the architectures for the models were not very deep. While many different
architectures were tested, only a few performed well. Once an architecture was
selected, this was again trained in many different iterations, producing about 50
different models. The best model was selected based on training and testing
accuracy. None of the models achieved higher than 83% accuracy during
training. This may have been due to the quality of the training dataset. Upon
inspection of the last MRIs of subjects used in the training set, some contained
ringing artifacts that may be preventing the model from reaching a higher training
accuracy.
Summary
Test set accuracy of each model was 70.1% and 73.3%, respectively.
However, comparing the histological model to a pathologist's annotations showed
a significant improvement in accuracy to 90.15%. Likewise, qualitative
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comparisons of the MRI predictions showed that the prediction maps
characterize the histological prediction of the same tissue.
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V. CONCLUSION

Test set accuracy of the histological and MRI model was 70.1% and
73.3%, respectively. However, comparing the histological model to a
pathologist's annotations showed a significant improvement in accuracy to
90.15%. Likewise, qualitative comparisons of the MRI predictions showed that
the prediction maps characterize the histological prediction of the same tissue.
This project found that it is possible to predict tumor presence in MRI
using histological images from pathologically validated tissue. It also
demonstated the efficacy of using a small, well-annotated dataset to classify a
much larger dataset, as well as a novel approach to quickly creating deep
annotations in histology. Using transfer learning, a pretrained AlexNet was able
to classify regions of tumor in H&E images across several subjects with good
accuracy. Additionally, despite the model not performing exceedingly well in the
test-set alone, looking at the images in their entirety, the annotations from the
pathologist and predictions align well with high accuracy.
This project accomplished the goal of showing that a histologically based
and pathologically verified MRI tumor predictor can be used to accurately identify
tumor. A weakly-classified dataset was used to generate this final model. The
efficacy of this model with an AUC of .75 leaves both room for improvement and
an impression of confidence in the methods presented. The limitations of this
study allow for potential future solutions to reduce the errors in the final model
and improve the overall accuracy.
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The results of both classifiers tell an important story. While they have their
limitations in their differing methods of data input, it is still noteworthy that the
MRI classifier did not generalize as well as the histological classifier. This
reiterates the point made at multiple institutions that a biopsy is the best way to
precisely diagnose a brain tumor. Because of that, it is imperative that
pathologically-validated datasets are used to train tumor predictions models.
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